A New Market Access Path for Repurposed Drugs

4 Pages Posted: 17 May 2014

See all articles by Dominique Pahud

Dominique Pahud

Novartis Pharmaceutical Corporation - Novartis Oncology

Lesa Mitchell

Techstars

John Wilbanks

Sage Bionetworks

Melissa Stevens

FasterCures

Scott Weir

University of Kansas Medical Center

John McBride

Tokai Pharmaceuticals

Lili Portilla

National Center for Advancing Translational Sciences, NIH

Ed Pezalla

Aetna

Michael Nameth

Town Total Healthcare

Bernadette O'Donoghue

Leukemia & Lymphoma Society

Arti K. Rai

Duke University School of Law; Duke Innovation & Entrepreneurship Initiative

Debra Lappin

Faegre Baker Daniels

Mary Ogle

Teva Pharmaceuticals

Scott Howell

Cardinal Health

Date Written: May 1, 2014

Abstract

A diverse set of stakeholders within health care came together in the fall of 2013 to brainstorm potential new commercial paths for repurposed drugs for the treatment of rare diseases. This report highlights some of the identified solutions that potentially could create the right set of incentives for the efficient and accelerated development and delivery of needed therapies for patients suffering from rare diseases.

Keywords: health care, pharmaceutical, drug, repurpose, innovation

Suggested Citation

Pahud, Dominique and Mitchell, Lesa and Wilbanks, John and Stevens, Melissa and Weir, Scott and McBride, John and Portilla, Lili and Pezalla, Ed and Nameth, Michael and O'Donoghue, Bernadette and Rai, Arti Kaur and Lappin, Debra and Ogle, Mary and Howell, Scott, A New Market Access Path for Repurposed Drugs (May 1, 2014). Available at SSRN: https://ssrn.com/abstract=2437502 or http://dx.doi.org/10.2139/ssrn.2437502

Dominique Pahud (Contact Author)

Novartis Pharmaceutical Corporation - Novartis Oncology ( email )

United States

Lesa Mitchell

Techstars ( email )

1828 Walnut, 3rd Floor
Kansas City, MO 64108
United States

John Wilbanks

Sage Bionetworks ( email )

1100 Fairview Ave. North
Seattle, WA 98109
United States

Melissa Stevens

FasterCures ( email )

1101 New York Avenue, NW
Suite 620
Washington, DC 20005
United States

HOME PAGE: http://www.fastercures.org/

Scott Weir

University of Kansas Medical Center ( email )

3901 Rainbow Boulevard
Kansas City, KS 66160
United States

HOME PAGE: http://www.kumc.edu/school-of-medicine/pharmacology-toxicology-and-therapeutics/faculty/scott-weir-p

John McBride

Tokai Pharmaceuticals

One Broadway, 14th floor
Cambridge, MA 02142
United States

HOME PAGE: http://www.tokaipharma.com

Lili Portilla

National Center for Advancing Translational Sciences, NIH ( email )

31 Center Drive, Suite 3B11
Bethesda, MD 20892-4874
United States

HOME PAGE: http://www.ncats.nih.gov/about/contact-us/contact-us.html

Ed Pezalla

Aetna ( email )

United States

Michael Nameth

Town Total Healthcare

532 Broadhollow Road
Suite 137
Melville, NY 11747
United States

HOME PAGE: http://www.towntotal.com/

Bernadette O'Donoghue

Leukemia & Lymphoma Society ( email )

1311 Mamaroneck Avenue, Suite 310
White Plains, NY 10605
United States

Arti Kaur Rai

Duke University School of Law ( email )

210 Science Drive
Box 90362
Durham, NC 27708
United States

Duke Innovation & Entrepreneurship Initiative ( email )

215 Morris St., Suite 300
Durham, NC 27701
United States

Debra Lappin

Faegre Baker Daniels ( email )

1050 K Street NW, Suite 400
Washington, DC 20001-4448
United States
202-312-7496 (Phone)

HOME PAGE: http://www.faegrebd.com

Mary Ogle

Teva Pharmaceuticals ( email )

5 Basel St. Petach Tikva
49131
Israel

HOME PAGE: http://www.tevapharm.com/

Scott Howell

Cardinal Health ( email )

7000 Cardinal Place
Dublin, OH 43017
United States

HOME PAGE: http://www.cardinal.com/us/en/essential-insights/Meet-the-experts

Do you have a job opening that you would like to promote on SSRN?

Paper statistics

Downloads
114
Abstract Views
1,619
rank
291,682
PlumX Metrics